Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 5:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 48,419 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: AS+ Clear all
Completed Phase 3 Interventional Results available

Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments

NCT02282020
View directory record Official record
Conditions
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
Interventions
OLAPARIB, Single agent chemotherapy
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Female only
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
22
States / cities
Birmingham, Alabama • Mobile, Alabama • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Oct 28, 2026, 5:28 PM EDT
Completed Not applicable Interventional

CARE Mentalizing-Focused Parenting Group Outcomes Study

NCT04580459
View directory record Official record
Conditions
Parent-Child Relationship, Parenting
Interventions
CARE Parenting Group Treatment, Treatment as Usual (TAU)
Behavioral
Lead sponsor
Montefiore Medical Center
Other
Eligibility
12 Years to 99 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 2, 2023 · Synced Oct 28, 2026, 5:28 PM EDT
Not listed Phase 1 Interventional

Phase 1A/1B Study of PSA/IL-2/GM-CSF Vaccine for Recurrent Prostate Cancer in Hormone Naive and Hormone Independent Patients

NCT02058680
View directory record Official record
Conditions
Prostate Cancer
Interventions
PSA/IL-2/GM-CSF
Biological
Lead sponsor
OncBioMune Pharmaceuticals
Other
Eligibility
18 Years and older · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Oct 28, 2026, 5:28 PM EDT
Completed Phase 2 Interventional Results available

Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)

NCT01490723
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
Rituximab, 111In Ibritumomab, Planar Scintigraphy Imaging, 90Y IbritumomabTiuxetan, Fludarabine, Bendamustine, Thymoglobulin, Tacrolimus, Methotrexate, Mycophenolate, G-CSF, Stem Cell Transplantation
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 5, 2020 · Synced Oct 28, 2026, 5:28 PM EDT
Recruiting Not applicable Interventional

Mobile Intervention for Suicidal Thoughts

NCT06593379
View directory record Official record
Conditions
Suicide
Interventions
Safety planning, Treatment as usual, MIST Intervention
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 28, 2026, 5:28 PM EDT
Completed Not applicable Interventional Results available

Patient-Centered Medication Adherence Intervention for Schizophrenia

NCT00144027
View directory record Official record
Conditions
Schizophrenia
Interventions
Antipsychotic medication adherence intervention
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 70 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
No. Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2015 · Synced Oct 28, 2026, 5:28 PM EDT
Completed No phase listed Observational Results available

COVID-19 Screening Program

NCT05216627
View directory record Official record
Conditions
COVID-19
Interventions
Self-administered saliva-based viral testing
Diagnostic Test
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Oct 28, 2026, 5:28 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Eye Movements and Reading Disabilities

NCT01860027
View directory record Official record
Conditions
Reading Disability, Dyslexia
Interventions
Not listed
Lead sponsor
Scripps Health
Other
Eligibility
7 Years to 13 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 22, 2023 · Synced Oct 28, 2026, 5:28 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Comprehensive Outcomes for After Cancer Health

NCT05349227
View directory record Official record
Conditions
Ovarian Cancer, Breast Cancer, Lung Cancer, Gastric Cancer, Survivorship, Endometrial Cancer, Head and Neck Cancers, Prostate Cancers, Geriatric Oncology, Metastatic Breast Cancer, Metastatic Cancer
Interventions
Digital Health Coaching Program, Fitbit
Behavioral · Device
Lead sponsor
Pack Health
Industry
Eligibility
18 Years and older
Enrollment
625 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
7
States / cities
Gainesville, Florida • Boston, Massachusetts • Omaha, Nebraska + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Oct 28, 2026, 5:28 PM EDT
Completed Phase 3 Interventional Results available

Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725

NCT00978380
View directory record Official record
Conditions
Congenital Bleeding Disorder, Congenital FXIII Deficiency
Interventions
catridecacog
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
6 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
12
States / cities
Orange, California • Washington D.C., District of Columbia • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Oct 28, 2026, 5:28 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

COVID-19 Serologic Strategies for Skilled Nursing Facilities

NCT05270980
View directory record Official record
Conditions
COVID-19
Interventions
Cohorting
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 6, 2023 · Synced Oct 28, 2026, 5:28 PM EDT
Completed Phase 2 Interventional Results available

Study to Allow Access to Single Agent Panobinostat for Patients Who Are on s.a. Panobinostat Treatment in a Novartis-sponsored Study and Continue to Benefit From the Treatment as Judged by the Investigator

NCT01802879
View directory record Official record
Conditions
Hematologic Neoplasms
Interventions
Panobinostat
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
4
States / cities
Duarte, California • Augusta, Georgia • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2019 · Synced Oct 28, 2026, 5:28 PM EDT
Completed No phase listed Observational

Patient-Reported Outcomes in Long-Term Survivors of Colon and Rectal Cancers

NCT00410579
View directory record Official record
Conditions
Colorectal Cancer, Fatigue, Long-term Effects Secondary to Cancer Therapy in Adults, Pain, Psychosocial Effects of Cancer and Its Treatment
Interventions
Telephone interview
Other
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
Not listed
Enrollment
744 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
200
States / cities
Aurora, Colorado • Boulder, Colorado • Colorado Springs, Colorado + 132 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2010 · Synced Oct 28, 2026, 5:28 PM EDT
Completed Not applicable Interventional Results available

Compassion Meditation for Older Adults

NCT03964246
View directory record Official record
Conditions
Anxiety and Mood Disorders
Interventions
Compassion Meditation (CM) intervention, Healthy Aging Psychoeducation
Behavioral · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
55 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 5, 2024 · Synced Oct 28, 2026, 5:28 PM EDT
Completed Not applicable Interventional

Reducing Stress in Adolescents and Young Adults With Type 1 Diabetes to Improve Diabetes Care

NCT02760303
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Cognitive Behavioral Therapy, Mindfulness Based Stress Reduction, Diabetes Support and Education
Behavioral
Lead sponsor
Wayne State University
Other
Eligibility
16 Years to 20 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 2, 2017 · Synced Oct 28, 2026, 5:28 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor

NCT00569127
View directory record Official record
Conditions
Colorectal Neuroendocrine Tumor G1, Gastric Neuroendocrine Tumor G1, Neuroendocrine Neoplasm, Neuroendocrine Tumor, Neuroendocrine Tumor G2
Interventions
Bevacizumab, Laboratory Biomarker Analysis, Octreotide Acetate, Recombinant Interferon Alfa-2b
Biological · Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
427 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2027
U.S. locations
493
States / cities
Mobile, Alabama • Fairbanks, Alaska • Fort Smith, Arkansas + 321 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 28, 2026, 5:28 PM EDT
Completed No phase listed Observational

Role of Social Incentives in PRO Collection

NCT03436446
View directory record Official record
Conditions
Orthopedic Disorder
Interventions
Interview
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 28, 2026, 5:28 PM EDT
Completed Not applicable Interventional

Longitudinal Effects of a Commercial Digital Weight Management Program on Weight Loss

NCT06666842
View directory record Official record
Conditions
Obesity, Weight Loss
Interventions
Noom Weight, Educational Control
Behavioral
Lead sponsor
Noom Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Oct 28, 2026, 5:28 PM EDT
Suspended Phase 2 Interventional

Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCC

NCT06860386
View directory record Official record
Conditions
Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma
Interventions
Pembrolizumab, Axitinib
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 28, 2026, 5:28 PM EDT
Not yet recruiting Not applicable Interventional

MRI and Local Anesthesia

NCT07602686
View directory record Official record
Conditions
Dental Anesthesia
Interventions
ddMRI
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 28, 2026, 5:28 PM EDT
Completed Phase 1 Interventional

A Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Crovalimab for the Management of Acute Uncomplicated Vaso-Occlusive Episodes (VOE) in Participants With Sickle Cell Disease (SCD).

NCT04912869
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Crovalimab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Atlanta, Georgia • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Oct 28, 2026, 5:28 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Wisconsin Evaluation of Emergency Department Care Coordination

NCT04550169
View directory record Official record
Conditions
Emergency Department Visit
Interventions
Intensive Care Coordination
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 64 Years
Enrollment
3,405 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
4
States / cities
Appleton, Wisconsin • Glendale, Wisconsin • Milwaukee, Wisconsin + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2025 · Synced Oct 28, 2026, 5:28 PM EDT
Terminated Phase 2 Interventional Results available

Lenalidomide (Revlimid®) as Second Line Therapy in Patients With Chronic Graft-Vs-Host Disease (GVHD)

NCT00675441
View directory record Official record
Conditions
Graft-versus-Host Disease
Interventions
Lenalidomide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2013 · Synced Oct 28, 2026, 5:28 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase 2 Study of Apixaban Reversal by Ciraparantag as Measured by WBCT

NCT03288454
View directory record Official record
Conditions
Healthy
Interventions
Ciraparantag, Placebo, Apixaban
Drug
Lead sponsor
Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
Industry
Eligibility
50 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Oct 28, 2026, 5:28 PM EDT